{"filing":{"accession_number":"0001193125-26-369426","cik":"0001755237","ticker":"CYCN","company_name":"Cyclerion Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-27","report_date":"2026-08-26","primary_document":"d264301d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1755237/000119312526369426/d264301d8k.htm"},"events":[{"id":29854,"run_id":27349,"accession_number":"0001193125-26-369426","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Cyclerion shareholders voted on August 26, 2026 to approve ten proposals central to a merger with Korsana, including the critical Nasdaq Stock Issuance Proposal (Proposal No. 1) approving issuance of shares representing more than 20% of outstanding stock and a change of control.","company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","filing_date":"2026-08-27","form":"8-K","submitted_at":null,"items":[{"id":32268,"accession_number":"0001193125-26-369426","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the final voting results from Cyclerion's August 26, 2026 annual shareholder meeting, including approval of ten proposals central to a merger transaction (the \"Merger Agreement\" with Korsana). The disclosure includes vote tallies for each proposal, including the critical Nasdaq Stock Issuance Proposal (Proposal No. 1), which approved issuance of shares representing more than 20% of outstanding stock and a change of control. This is a material shareholder vote result directly tied to M\u0026A activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T10:08:06.769541+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":29855,"run_id":27349,"accession_number":"0001193125-26-369426","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Cyclerion shareholders and the board approved a 1-for-7 reverse stock split in connection with the pending merger with Korsana, with the combined company expected to list on Nasdaq under a new name and ticker symbol upon merger consummation.","company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","filing_date":"2026-08-27","form":"8-K","submitted_at":null,"items":[{"id":32269,"accession_number":"0001193125-26-369426","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on shareholder approval and board approval of a reverse stock split (1-for-7) in connection with a pending merger with Korsana, followed by the combined company's expected listing on Nasdaq under a new name and ticker symbol. While the reverse stock split itself is a capital structure event, the context makes clear this is part of a material acquisition/merger transaction (\"Prior to the closing of the Merger,\" \"consummation of the Merger,\" \"Combined Company\"). The merger is the principal material event; the reverse split is a preparatory step within that M\u0026A activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T10:08:06.769541+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32268,"accession_number":"0001193125-26-369426","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the final voting results from Cyclerion's August 26, 2026 annual shareholder meeting, including approval of ten proposals central to a merger transaction (the \"Merger Agreement\" with Korsana). The disclosure includes vote tallies for each proposal, including the critical Nasdaq Stock Issuance Proposal (Proposal No. 1), which approved issuance of shares representing more than 20% of outstanding stock and a change of control. This is a material shareholder vote result directly tied to M\u0026A activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T10:08:06.769541+00:00","company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","filing_date":"2026-08-27"},{"id":32269,"accession_number":"0001193125-26-369426","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on shareholder approval and board approval of a reverse stock split (1-for-7) in connection with a pending merger with Korsana, followed by the combined company's expected listing on Nasdaq under a new name and ticker symbol. While the reverse stock split itself is a capital structure event, the context makes clear this is part of a material acquisition/merger transaction (\"Prior to the closing of the Merger,\" \"consummation of the Merger,\" \"Combined Company\"). The merger is the principal material event; the reverse split is a preparatory step within that M\u0026A activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T10:08:06.769541+00:00","company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","filing_date":"2026-08-27"}]}